(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...
The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be fu ...
Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company"), a biopharmaceutical company focused on developing innovative immune restoration therapies ...
(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...
Zacks.com on MSN9h
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins DeclineGlaukos Corporation GKOS reported fourth-quarter 2024 adjusted loss of 40 cents per share, narrower than the Zacks Consensus ...
Hosted on MSN6h
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some promising results.
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...
Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...
Rusfertide: Protagonist held an in-person PV Day on February 6, 2025, in New York; The topline data for the Phase 3 VERIFY study in PV, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback